This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Since the introduction of cystic fibrosis transmembrane conductance regulator modulators (CFTRm), more females with cystic fibrosis (CF) are becoming pregnant. Prior to the CFTRm era, pregnancy was associated with increased pulmonary exacerbations and decline in lung function. We hypothesize that in the CFTRm era, pregnant and non-pregnant females with CF would have similar rates of pulmonary exacerbations rates and lung function trajectories. METHODS: We analyzed data from the CF Foundation Patient Registry (CFFPR) (2012-2022) to evaluate females ages 18-50 years who had ever experienced a pregnancy versus those who had never been pregnant. We assessed pulmonary exacerbation events and changes in percent predicted forced expiratory volume in 1 second (ppFEV1) over time by conducting longitudinal regression models using the generalized estimating equation method after adjusting for key covariates. RESULTS: Among 5609 eligible females, 3402 (61%) had never been pregnant and 2207 (39%) had at least one pregnancy. Elexacaftor/tezacaftor/ivacaftor (ETI) use was more common among pregnant than non-pregnant females (72%vs. 59%; p < 0.0001). The adjusted annual pulmonary exacerbation rate did not differ between groups [adjusted rate ratio 1.03, 95% CI 0.97-1.08; p = 0.35]. Pregnant females had higher ppFEV1 at all time points but the rate of change over time was similar between groups (interaction p = 0.55). CONCLUSIONS: In the CFTRm era, pregnancy was not associated with increased pulmonary exacerbation rates or accelerated decline in ppFEV1. These findings provide reassuring evidence to support counseling of females with CF who are considering pregnancy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bionghi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: